Elena Favaro
Copenhagen, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Exposure-Response Analyses to Inform the Optimal Epcoritamab Monotherapy Dosing Regimen in Relapsed or Refractory Follicular Lymphoma.
Journal: Clinical pharmacokinetics
Published: March 09, 2026
Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity.
Journal: Clinical and translational science
Published: November 24, 2025
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
Journal: Lancet (London, England)
Published: October 24, 2025
Clinical representativeness of pivotal trials for T-cell engagers in relapsed/refractory follicular lymphoma.
Journal: Future oncology (London, England)
Published: August 13, 2025
Three-year follow-up of epcoritamab therapy in Japanese patients with relapsed/refractory follicular lymphoma in EPCORE NHL-3.
Journal: International journal of hematology
Published: July 28, 2025
Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial.
Journal: Leukemia & lymphoma
Published: July 09, 2025
Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial.
Journal: International journal of clinical oncology
Published: March 13, 2025
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study.
Journal: The Lancet. Haematology
Published: April 08, 2024
Last Updated: 09/26/2026